LAMAs were largely prescribed for patients in Turkey who had uncontrolled asthma, older age, obesity, exacerbations, and/or ...
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback